

Refine Search

Search Results -

Term	Documents
EPC	6587
EPCS	434
ENDOTHELIAL	62036
ENDOTHELIALS	17
PROGENITOR	18271
PROGENITORS	8820
PRECURSOR	244432
PRECURSORS	136575
(4 AND (EPC OR (ENDOTHELIAL ADJ (PROGENITOR OR PRECURSOR))))).PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD.	164
(L4 AND (EPC OR (ENDOTHELIAL ADJ (PROGENITOR OR PRECURSOR))))).PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD.	164

Database:

US Pre-Grant Publication Full-Text Database
 US Patents Full-Text Database
 US OCR Full-Text Database
 EPO Abstracts Database
 JPO Abstracts Database
 Derwent World Patents Index
 IBM Technical Disclosure Bulletins

Search:

L5

Refine Search

Recall Text

Clear

Interrupt

Search History

DATE: Monday, February 19, 2007 [Purge Queries](#) [Printable Copy](#) [Create Case](#)

Set
Name **Query**
 side by
 side

Hit
Count

Set
Name
 result set

DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; THES=ASSIGNEE; PLUR=YES;
 OP=AND

<u>L5</u>	L4 and (EPC or (endothelial adj (progenitor or precursor)))	164	<u>L5</u>
<u>L4</u>	(vector or DNA or (nucleic adj acid)) same (angiogenic adj (protein or factor))	1266	<u>L4</u>
<u>L3</u>	L2 and (GM-CSF or G-CSF or M-CSF or SCF or SLF or (steel adj factor))	2986	<u>L3</u>
<u>L2</u>	(myocardial or cardiomyopathy or heart) same (ischemic or ischemia)	34679	<u>L2</u>
<u>L1</u>	Asahara-Takayuki.in.	22	<u>L1</u>

END OF SEARCH HISTORY

Welcome to DialogClassic Web(tm)

Dialog level 05.16.01D
Last logoff: 17feb07 10:15:03
Logon file001 19feb07 16:07:25

***** ANNOUNCEMENTS *****

NEW FILES RELEASED

***Engineering Index Backfile (File 988)
***EMCare (File 45)
***Trademarkscan - South Korea (File 655)

RESUMED UPDATING

***File 141, Reader's Guide Abstracts

RELOADS COMPLETED

***Files 340, 341 & 942, CLAIMS/U.S. Patents - 2006 reload now online
***Files 173 & 973, Adis Clinical Trials Insight

DATABASES REMOVED

Chemical Structure Searching now available in Prous Science Drug
Data Report (F452), Prous Science Drugs of the Future (F453),
IMS R&D Focus (F445/955), Pharmaprojects (F128/928), Beilstein
Facts (F390), Derwent Chemistry Resource (F355) and Index Chemicus
(File 302).

*** >>>For the latest news about Dialog products, services, cont
>>>and events, please visit What's New from Dialog at <<<
>>><http://www.dialog.com/whatsnew/>. You can find news about<<<
>>>a specific database by entering HELP NEWS <file number>.<<<
>>>PROFILE is in a suspended state.
>>>Contact Dialog Customer Services to re-activate it.
* * *

File 1:ERIC 1965-2007/Jan
(c) format only 2007 Dialog

Set	Items	Description
-----	-------	-------------

Cost is in DialUnits
?

B 155, 5, 73
19feb07 16:07:46 User259876 Session D979.1
\$0.93 0.266 DialUnits File1
\$0.93 Estimated cost File1
\$0.08 INTERNET
\$1.01 Estimated cost this search
\$1.01 Estimated total session cost 0.266 DialUnits

SYSTEM:OS - DIALOG OneSearch

File 155:MEDLINE(R) 1950-2007/Feb 16
(c) format only 2007 Dialog

***File 155: MEDLINE has resumed updating with UD20061209. Please
see HELP NEWS 154 for details.**

File 5:Biosis Previews(R) 1969-2007/Feb W2
(c) 2007 The Thomson Corporation

***File 5: In preparation for coming enhancements, accession numbers will
change soon. See HELP NEWS 5 for details.**

File 73:EMBASE 1974-2007/Feb 19
(c) 2007 Elsevier B.V.

Set	Items	Description
?		
S		(MYOCARDIAL OR CARDIOMYOPATHY OR HEART) (S) ISCHEMIC OR ISCHEMIA)
>>>		Unmatched parentheses
?		
S		(MYOCARDIAL OR CARDIOMYOPATHY OR HEART) (S) (ISCHEMIC OR ISCHEMIA)
	597595	MYOCARDIAL
	101418	CARDIOMYOPATHY
	2103372	HEART
	338396	ISCHEMIC
	402078	ISCHEMIA
S1	254404	(MYOCARDIAL OR CARDIOMYOPATHY OR HEART) (S) (ISCHEMIC OR ISCHEMIA)
?		
S S1 AND		(GM-CSF OR G-CSF OR M-CSF OR SCF OR SLF OR (STEEL (W) FACTOR))
	254404	S1
	3694	GM-CSF
	1247	G-CSF
	388	M-CSF
	12196	SCF
	600	SLF
	37354	STEEL
	2703340	FACTOR
	1771	STEEL(W) FACTOR
S2	49	S1 AND (GM-CSF OR G-CSF OR M-CSF OR SCF OR SLF OR (STEEL (W) FACTOR))
?		
S		(VECTOR OR DNA) (S) (ANGIOGENIC (W) (PROTEIN OR FACTOR))
Processing		
	324907	VECTOR
	2744426	DNA
	37186	ANGIOGENIC
	4854222	PROTEIN
	2703340	FACTOR
S3	300	(VECTOR OR DNA) (S) (ANGIOGENIC (W) (PROTEIN OR FACTOR))
?		
S S2 AND S3		
	49	S2
	300	S3
S4	0	S2 AND S3
?		
Set	Items	Description
S1	254404	(MYOCARDIAL OR CARDIOMYOPATHY OR HEART) (S) (ISCHEMIC OR I-SCHEMIA)
S2	49	S1 AND (GM-CSF OR G-CSF OR M-CSF OR SCF OR SLF OR (STEEL (-W) FACTOR))
S3	300	(VECTOR OR DNA) (S) (ANGIOGENIC (W) (PROTEIN OR FACTOR))
S4	0	S2 AND S3
?		
S S2 AND		(EPC OR (ENDOTHELIAL (W) (PROGENITOR OR PRECURSOR)))

49 S2
 3852 EPC
 408553 ENDOTHELIAL
 88591 PROGENITOR
 261509 PRECURSOR
 3379 ENDOTHELIAL(W) (PROGENITOR OR PRECURSOR)
 S5 7 S2 AND (EPC OR (ENDOTHELIAL (W) (PROGENITOR OR
 PRECURSOR)))

?

RD

S6 7 RD (unique items)

?

T S6/3,K/ALL

6/3,K/1 (Item 1 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2007 Dialog. All rts. reserv.

14517800 PMID: 14521750

[Transplantation of cord blood endothelial progenitor cells ameliorates limb ischemia]

Yang Chen; Zhang Zhi-hua; Lu Shi-hong; Yang Ren-chi; Qian Guan-qing; Han Zhong-chao

State Key Laboratory of Experimental Hematology, Institute of Hematology, Peking Union Medical College, Tianjin 300020, China.

Zhonghua yi xue za zhi (China) Aug 25 2003, 83 (16) p1437-41, ISSN 0376-2491--Print Journal Code: 7511141

Publishing Model Print

Document type: Journal Article ; English Abstract

Languages: CHINESE

Main Citation Owner: NLM

Record type: MEDLINE; Completed

[Transplantation of cord blood endothelial progenitor cells ameliorates limb ischemia]

OBJECTIVE: To investigate the feasibility of transplanting cord blood CD133+ cells derived endothelial progenitor cells (EPC) in therapeutic vasculogenesis. METHODS: CD133+ cells from the cord blood of 52 neonates were cultured...

...VEGF), 20 ng/ml interleukin-3 (IL-3) and 50 ng/ml stem cell factor (SCF). The cell markers of spindle-shaped adherent cells were determined with flow cytometry. The left...

...vein, and muscular branch of 22 Balb/c nude mice were cut to cause limb ischemia . One day after the unilateral ischemic limb surgery half million adherent cells were transplanted into 12 nude mice via tail vein (EPC group) and M199 was injected into the tail veins of 10 nude mice (M199 group...

...used to trace the transplanted cells and monitor the blood perfusion and capillary density of ischemic limbs. The ratio between the blood perfusion of the operated limb and of the non...

...limbs were taken to count the number of capillaries. The VEGF mRNA levels of the ischemic and nonischemic limbs were examined with semi-quantitative RT-PCR. Seven days after the operation...

... FITC)-binded ulex europaeus agglutinin-1 (UEA-1) was injected via tail

vein to 3 EPC group mice. Thirty minutes later, the mice were killed. The heart, lung, liver, spleen and limb muscles were taken and examined with fluorescence microscopy. EPC were added into the upper chamber of Coster Transwell and chemotactic fluids of M199 with or without VEGE were added into the lower chamber. Four hours later the number of EPC in the lower chamber was counted so as to examine the chemotactic effect of VEGE...

... CD31, von Willebrand factor (vWF) and combined with ulex europaeus agglutinin-1 (UEA-1). Transplanted EPC survived and were incorporated into the capillary networks in the ischemic limbs of nude mice. The ratio between the blood perfusion of the ischemic limb and non-ischemic limbs was 19.1% +/- 3.1%. Two weeks after the transplantation, the ratio between the blood perfusion of the ischemic limb and non-ischemic limbs of the EPC group was 77.3% +/- 5.6%, significantly higher than that of the M199 group (40...

...001). CD31 histochemical staining showed that the density of capillaries in the gastrocnemius muscles of ischemic hind limb was significantly higher 7, 14, and 21 days after operation in the EPC group than in the M199 group ($P < 0.05$). RT-PCR showed obvious VEGF bands in the ischemic hind limb muscles, but not in the non-ischemic muscles. The number of EPC immigrating into the lower chamber of the Coster Transwell was 817 +/- 32.5, significantly higher...

... control group (473.5 +/- 61.5, $P < 0.05$). CONCLUSION: Cord blood CD133+ cells derived EPC is a robust cell source for therapeutic neovascularization. Upregulated expression of VEGF may account for the homing of transplanted EPC to ischemic tissue.

6/3,K/2 (Item 1 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2007 The Thomson Corporation. All rts. reserv.

19119884 BIOSIS NO.: 200600465279

Therapeutic angiogenesis - Another passing phase?

AUTHOR: Semenza Gregg L (Reprint)

AUTHOR ADDRESS: Johns Hopkins Univ, Sch Med, Vasc Biol Program, Inst Cell Engn, Dept Pediat, Broadway Res Bldg, Suite 671, 733 N Broadway, Baltimore, MD 21205 USA**USA

AUTHOR E-MAIL ADDRESS: gsemenza@jhmi.edu

JOURNAL: Circulation Research 98 (9): p1115-1116 MAY 12 2006 2006

ISSN: 0009-7330

DOCUMENT TYPE: Article; Editorial

RECORD TYPE: Citation

LANGUAGE: English

...REGISTRY NUMBERS: GM-CSF

DESCRIPTORS:

...ORGANISMS: PARTS ETC: endothelial progenitor cell

...DISEASES: myocardial ischemia --...

... heart disease, vascular disease, drug therapy, therapy

...MESH TERMS: Myocardial Ischemia (MeSH)

CHEMICALS & BIOCHEMICALS: ... GM-CSF

6/3,K/3 (Item 2 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2007 The Thomson Corporation. All rts. reserv.

19033458 BIOSIS NO.: 200600378853

Combined administration of G-CSF and GM-CSF stimulates monocyte-derived pro-angiogenic cells in patients with acute myocardial infarction

AUTHOR: Bruno Stefania; Bussolati Benedetta; Scacciatella Paolo; Marra Sebastiano; Sanavio Fiorella; Tarella Corrado; Camussi Giovanni (Reprint)
 AUTHOR ADDRESS: Osped Maggiore S Giovanni Battista, Dipartimento Med Interna, Cattedra Nefrol, Corso Dogliotti 14, I-10126 Turin, Italy**Italy
 AUTHOR E-MAIL ADDRESS: giovanni.camussi@unito.it
 JOURNAL: Cytokine 34 (1-2): p56-65 APR 2006 2006
 ISSN: 1043-4666
 DOCUMENT TYPE: Article
 RECORD TYPE: Abstract
 LANGUAGE: English

ABSTRACT: Mobilization of endothelial progenitor cells has been suggested to contribute to neo-vascularization of ischemic organs. Aim of this study was to investigate whether the combination of granulocyte colony stimulating...

...macrophage (GM)-CSF may influence the expansion of circulating KDR+ cells in patients with acute myocardial infarction (AMI). KDR+ cells significantly increased in peripheral blood of AMI patients treated with G...

...REGISTRY NUMBERS: GM-CSF

DESCRIPTORS:

...ORGANISMS: PARTS ETC: endothelial progenitor cell

6/3,K/4 (Item 3 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2007 The Thomson Corporation. All rts. reserv.

18572325 BIOSIS NO.: 200510266825

Intracardiac transplantation of already specifically dedifferentiated circulating CD34(+) cell subsets would favor post-ischemic myocardial regeneration

AUTHOR: Henon Philippe R G (Reprint); Sovalat Hanna; Ojeda-Urbe Mario; Arkam Yazid; Bischoff Nicolas; Monassier Jean- Pierre; Dallemand Robert
 AUTHOR ADDRESS: Hop Emile Muller, Dept Hematol, Mulhouse, France**France
 JOURNAL: Blood 104 (11, Part 2): p130B NOV 16 2004 2004
 CONFERENCE/MEETING: 46th Annual Meeting of the American-Society-of-Hematology San Diego, CA, USA December 04 -07, 2004; 20041204
 SPONSOR: Amer Soc Hematol
 ISSN: 0006-4971
 DOCUMENT TYPE: Meeting; Meeting Abstract
 RECORD TYPE: Abstract
 LANGUAGE: English

Intracardiac transplantation of already specifically dedifferentiated circulating CD34(+) cell subsets would favor post- ischemic myocardial regeneration

...ABSTRACT: in which autologous bone marrow (BM) mononuclear cells (MNCs) were reinjected either directly in the ischemic area or intra-coronary in patients with severe post-infarct cardiac failure, resulting in a...

...improvement. Moreover, the obstructed coronary artery was always reperfused, which biases the evaluation of posttransplant myocardial reperfusion. We have personally chosen an other original

approach using mobilized and purified circulating CD34...

...are immunophenotypically characterized either as mature (CD34(+)/VEGFR-2(+)) or immature (CD34(+)/133(+)/VEGFR-2(+)) endothelial progenitor cells - thus potentially capable of neoangiogenesis -, or as muscle progenitors (Desmin(+)) and even more as cardiomyocytes...

DESCRIPTORS:

...ORGANISMS: PARTS ETC: endothelial progenitor cell
CHEMICALS & BIOCHEMICALS: ... G-CSF

6/3,K/5 (Item 4 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2007 The Thomson Corporation. All rts. reserv.

18554098 BIOSIS NO.: 200510248598

Endothelial progenitor cells as potential drug targets

AUTHOR: Thum T (Reprint); Bauersachs J

AUTHOR ADDRESS: Univ Wurzburg, Univ Klinikum, Med Klin and Poliklin 1,
Josef Schneider Str 2, D-97080 Wurzburg, Germany**Germany

AUTHOR E-MAIL ADDRESS: ThumT@medizin.uni-wuerzburg.de

JOURNAL: Current Drug Targets - Cardiovascular & Haematological Disorders
5 (4): p277-286 AUG 2005 2005

ISSN: 1568-0061

DOCUMENT TYPE: Article

RECORD TYPE: Citation

LANGUAGE: English

Endothelial progenitor cells as potential drug targets

...REGISTRY NUMBERS: GM-CSF

DESCRIPTORS:

...ORGANISMS: PARTS ETC: endothelial progenitor cells
...DISEASES: cardiac ischemia --...

... heart disease, drug therapy

...MESH TERMS: Myocardial Ischemia (MeSH)

CHEMICALS & BIOCHEMICALS: ... GM-CSF

6/3,K/6 (Item 5 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2007 The Thomson Corporation. All rts. reserv.

17766361 BIOSIS NO.: 200400133715

Intra-cardiac reinjection of purified autologous blood CD34+ cells mobilized by G-CSF can significantly improve myocardial function in cardiac patients. .

AUTHOR: Henon Philippe R G (Reprint); Ojeda Mario (Reprint); Arkam Yazid (Reprint); Sovalat Hanna (Reprint); Bischoff Nicolas; Monassier Jean-Pierre; Brink Ingo

AUTHOR ADDRESS: IRHT-Hopital du Hasenrain, Mulhouse, France**France

JOURNAL: Blood 102 (11): p335a November 16, 2003 2003

MEDIUM: print

CONFERENCE/MEETING: 45th Annual Meeting of the American Society of Hematology San Diego, CA, USA December 06-09, 2003; 20031206

SPONSOR: American Society of Hematology

ISSN: 0006-4971

DOCUMENT TYPE: Meeting; Meeting Abstract; Meeting Poster

RECORD TYPE: Abstract

LANGUAGE: English

...ABSTRACT: high potential for angiogenetic or cardiomyocytic differentiation. Ten patients suffering from severe cardiac failure after myocardial infarct (MI) are scheduled over one year according to the following criteria: left-ventricular ejection...

...area. Besides, flow cytometry evaluation of total CD34+ cells and of the CD133+, CD133+KDR+ (endothelial progenitor cells) and Desmin+ (marking contractile muscular cells) CD34+ subsets reinjected is systematically performed. 3 patients...

...received the lowest cell amounts did not show any significant improvement of neither LVEF (5%), myocardial contractility nor reperfusion. On the contrary, the two other patients for whom the MI was ...

...very preliminary data that G-CSF CD34+ cell mobilization, apheresis session(s) and subsequent intra- myocardial cell reinjection are feasible and safe in patients with extended MI; mobilized CD34+ cells contain...

...may play a significant role in the improvement in viability, contractility and reperfusion of the ischemic zone. Time between MI occurrence and cell transplantation as well as numbers and subvarieties of...

...REGISTRY NUMBERS: G-CSF

6/3,K/7 (Item 6 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2007 The Thomson Corporation. All rts. reserv.

17408852 BIOSIS NO.: 200300367571

Capacity of G-CSF To Mobilize Endothelial Progenitor Cells into the Peripheral Blood of Stem Cell Donors.

AUTHOR: Seitz Gabriele (Reprint); Kimura Takafumi (Reprint); Wiesner Tina (Reprint); Pereira Daniel S (Reprint); Kanz Lothar (Reprint); Mohle Robert (Reprint)

AUTHOR ADDRESS: Department of Medicine II, University of Tübingen, Tübingen, Germany**Germany

JOURNAL: Blood 100 (11): pAbstract No. 4087 November 16, 2002 2002

MEDIUM: print

CONFERENCE/MEETING: 44th Annual Meeting of the American Society of Hematology Philadelphia, PA, USA December 06-10, 2002; 20021206

SPONSOR: American Society of Hematology

ISSN: 0006-4971

DOCUMENT TYPE: Meeting; Meeting Poster; Meeting Abstract

RECORD TYPE: Abstract

LANGUAGE: English

Capacity of G-CSF To Mobilize Endothelial Progenitor Cells into the Peripheral Blood of Stem Cell Donors.

ABSTRACT: Endothelial progenitor cells (EPC) may be useful to induce angiogenesis and neovascularisation and could potentially be applied in the treatment of ischemic lesions (e.g. myocardial infarction). It has been shown that EPC circulate in the peripheral blood and express the phenotype CD34+/VEGFR2+/VE-Cadherin+. To explore the capacity of G-CSF to mobilize EPC in humans, CD34+ progenitor cells were isolated from peripheral blood of stem cell donors and...

...Cadherin+: 0.32+/- 0.09, n=15). In order to study the functional potency of EPC in G-CSF mobilized peripheral blood, mononuclear cells, lineage-negative (Lin-) cells and Lin-/VEGFR2...

...per 10e4 input cells after VEGFR2 selection, demonstrating that the antibody is able to enrich EPC. Although EPC can be detected in G-CSF mobilized CD34+ cells, the frequency is rather low. Therefore, G-CSF is not sufficient to mobilize EPC in quantities which could effectively be isolated for therapeutical purposes. Other cytokines, e.g. VEGF, might be more appropriate for mobilization of EPC from the bone marrow, as it was demonstrated in recent animal studies, but this approach...

...REGISTRY NUMBERS: G-CSF

DESCRIPTORS:

ORGANISMS: PARTS ETC: endothelial progenitor cells...

?

Set	Items	Description
S1	254404	(MYOCARDIAL OR CARDIOMYOPATHY OR HEART) (S) (ISCHEMIC OR I-SCHEMIA)
S2	49	S1 AND (GM-CSF OR G-CSF OR M-CSF OR SCF OR SLF OR (STEEL (-W) FACTOR))
S3	300	(VECTOR OR DNA) (S) (ANGIOGENIC (W) (PROTEIN OR FACTOR))
S4	0	S2 AND S3
S5	7	S2 AND (EPC OR (ENDOTHELIAL (W) (PROGENITOR OR PRECURSOR)))
S6	7	RD (unique items)

?

S S3 AND (EPC OR (ENDOTHELIAL (W) (PROGENITOR OR PRECURSOR)))

300	S3
3852	EPC
17	ENDOTHELIAL
88591	PROGENITOR
261509	PRECURSOR
0	ENDOTHELIAL(W) (PROGENITOR OR PRECURSOR)
S7	0 S3 AND (EPC OR (ENDOTHELIAL (W) (PROGENITOR OR PRECURSOR)))

?

Set	Items	Description
S1	254404	(MYOCARDIAL OR CARDIOMYOPATHY OR HEART) (S) (ISCHEMIC OR I-SCHEMIA)
S2	49	S1 AND (GM-CSF OR G-CSF OR M-CSF OR SCF OR SLF OR (STEEL (-W) FACTOR))
S3	300	(VECTOR OR DNA) (S) (ANGIOGENIC (W) (PROTEIN OR FACTOR))
S4	0	S2 AND S3
S5	7	S2 AND (EPC OR (ENDOTHELIAL (W) (PROGENITOR OR PRECURSOR)))
S6	7	RD (unique items)
S7	0	S3 AND (EPC OR (ENDOTHELIAL (W) (PROGENITOR OR PRECURSOR)-))

?

S S3 AND (GM-CSF OR G-CSF OR M-CSF OR SLF OR SCF)

300	S3
3694	GM-CSF
1247	G-CSF
388	M-CSF
600	SLF
12196	SCF

S8 0 S3 AND (GM-CSF OR G-CSF OR M-CSF OR SLF OR SCF)

?

Set	Items	Description
S1	254404	(MYOCARDIAL OR CARDIOMYOPATHY OR HEART) (S) (ISCHEMIC OR I-SCHEMIA)
S2	49	S1 AND (GM-CSF OR G-CSF OR M-CSF OR SCF OR SLF OR (STEEL (-W) FACTOR))
S3	300	(VECTOR OR DNA) (S) (ANGIOGENIC (W) (PROTEIN OR FACTOR))
S4	0	S2 AND S3
S5	7	S2 AND (EPC OR (ENDOTHELIAL (W) (PROGENITOR OR PRECURSOR)))
S6	7	RD (unique items)
S7	0	S3 AND (EPC OR (ENDOTHELIAL (W) (PROGENITOR OR PRECURSOR)-))
S8	0	S3 AND (GM-CSF OR G-CSF OR M-CSF OR SLF OR SCF)

?

S S3 AND (BONE (W) MARROW (W) MOBILIZATION)

300	S3
1298251	BONE
478715	MARROW
90550	MOBILIZATION
37	BONE(W)MARROW(W)MOBILIZATION

S9 0 S3 AND (BONE (W) MARROW (W) MOBILIZATION)

?

Set	Items	Description
S1	254404	(MYOCARDIAL OR CARDIOMYOPATHY OR HEART) (S) (ISCHEMIC OR I-SCHEMIA)
S2	49	S1 AND (GM-CSF OR G-CSF OR M-CSF OR SCF OR SLF OR (STEEL (-W) FACTOR))
S3	300	(VECTOR OR DNA) (S) (ANGIOGENIC (W) (PROTEIN OR FACTOR))
S4	0	S2 AND S3
S5	7	S2 AND (EPC OR (ENDOTHELIAL (W) (PROGENITOR OR PRECURSOR)))
S6	7	RD (unique items)
S7	0	S3 AND (EPC OR (ENDOTHELIAL (W) (PROGENITOR OR PRECURSOR)-))
S8	0	S3 AND (GM-CSF OR G-CSF OR M-CSF OR SLF OR SCF)
S9	0	S3 AND (BONE (W) MARROW (W) MOBILIZATION)

?

S S2 AND (BONE (W) MARROW (W) MOBILIZATION)

49	S2
1298251	BONE
478715	MARROW
90550	MOBILIZATION
37	BONE(W)MARROW(W)MOBILIZATION

S10 1 S2 AND (BONE (W) MARROW (W) MOBILIZATION)

?

T S10/3,K/ALL

10/3,K/1 (Item 1 from file: 5)
 DIALOG(R)File 5: Biosis Previews(R)
 (c) 2007 The Thomson Corporation. All rts. reserv.

17692570 BIOSIS NO.: 200400063327

Synergistic effect of bone marrow mobilization and VEGF-2 gene transfer in

chronic myocardial ischemia.

AUTHOR: Kawamoto Atsuhiko (Reprint); Kusano Kengo (Reprint); Tkebuchava Tengiz (Reprint); Shintani Satoshi (Reprint); Johnson Ingrid (Reprint); Murayama Toshinori (Reprint); Samson Patrick (Reprint); Hanley Allison (Reprint); Ma Hong (Reprint); Silver Marcy (Reprint); Kearney Marianne (Reprint); Losordo Douglas W (Reprint)

AUTHOR ADDRESS: St. Elizabeth's Med Cntr, Boston, MA, USA**USA

JOURNAL: Circulation 108 (17 Supplement): pIV-144 October 28, 2003 2003

MEDIUM: print

CONFERENCE/MEETING: American Heart Association Scientific Sessions 2003 Orlando, FL, USA November 09-12, 2003; 20031109

SPONSOR: American Heart Association

ISSN: 0009-7322 (ISSN print)

DOCUMENT TYPE: Meeting; Meeting Abstract

RECORD TYPE: Citation

LANGUAGE: English

Synergistic effect of bone marrow mobilization and VEGF-2 gene transfer in chronic myocardial ischemia .

...REGISTRY NUMBERS: G-CSF

DESCRIPTORS:

DISEASES: chronic myocardial ischemia --....

... heart disease, vascular disease

MESH TERMS: Myocardial Ischemia (MeSH)

METHODS & EQUIPMENT: bone marrow mobilization --

?

Set	Items	Description
S1	254404	(MYOCARDIAL OR CARDIOMYOPATHY OR HEART) (S) (ISCHEMIC OR I-SCHEMIA)
S2	49	S1 AND (GM-CSF OR G-CSF OR M-CSF OR SCF OR SLF OR (STEEL (-W) FACTOR))
S3	300	(VECTOR OR DNA) (S) (ANGIOGENIC (W) (PROTEIN OR FACTOR))
S4	0	S2 AND S3
S5	7	S2 AND (EPC OR (ENDOTHELIAL (W) (PROGENITOR OR PRECURSOR)))
S6	7	RD (unique items)
S7	0	S3 AND (EPC OR (ENDOTHELIAL (W) (PROGENITOR OR PRECURSOR)-))
S8	0	S3 AND (GM-CSF OR G-CSF OR M-CSF OR SLF OR SCF)
S9	0	S3 AND (BONE (W) MARROW (W) MOBILIZATION)
S10	1	S2 AND (BONE (W) MARROW (W) MOBILIZATION)

?

COST

```

19feb07 16:15:55 User259876 Session D979.2
  $4.73    1.392 DialUnits File155
    $0.22  1 Type(s) in Format  3
    $0.22  1 Types
$4.95 Estimated cost File155
  $7.98    1.331 DialUnits File5
    $15.40  7 Type(s) in Format  3
    $15.40  7 Types
$23.38 Estimated cost File5
  $14.45    1.214 DialUnits File73
$14.45 Estimated cost File73
      OneSearch, 3 files,  3.937 DialUnits FileOS.
  $2.40 INTERNET
$45.18 Estimated cost this search

```

\$46.19 Estimated total session cost 4.203 DialUnits

?

Return to logon page!



Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.
Additionally, enter the **first few letters** of the Inventor's First name.

Last Name**First Name**

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)